Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of UCB7665 in Healthy Subjects
NCT02220153Phase 1Completed
- Sponsor
- UCB
- Start
- Jul 2014
- Primary completion
- Sep 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rozanolixizumab in myasthenia gravis (MG) and immune thrombocytopenia (ITP) (9 arms), sponsored by UCB. Primary endpoint: Incidence of adverse events. Started Jul 2014; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT02220153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02220153.